Clinical trials: Esomeprazole
GERD
Nexium RESPONSE Trial
The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.
- Trial name
- NCT00318968
- Testing
- Esomeprazole
- Where
- 38 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Healthy
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects
This study aims to evaluate the effects of tegoprazan or esomeprazole administered in combination with clopidogrel on the pharmacodynamics/Pharmacokinetics of clopidogrel in healthy adults
- Trial name
- NCT06164834
- Testing
- Clopidogrel 75 mg, Tegoprazan 25 mg, Esomeprazole 20mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy
Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males
The purpose of this study is to evaluate the pharmacokinetic profile of Esomeprazole (D961H) during repeated oral administration with and without co-administration of loxoprofen and the pharmacokinetic profile of loxoprofen…
- Trial name
- NCT00676117
- Testing
- Esomeprazole (D961H), Loxoprofen
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration
The present study will be conducted in order to compare the bioavailability of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland) and of INexium 40 mg MUPS tablets (AstraZeneca, France) under single dose fasted and fed…
- Trial name
- NCT00889850
- Testing
- 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland), INexium 40 mg MUPS tablets (AstraZeneca, France)
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mepha Ltd.
Gastro-Oesophageal Reflux Disease
PPI Sequencing Study
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NCT00384592
- Testing
- Esomeprazole, Physical exam, Pregnancy test if applicable
- Where
- 14 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis
This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.
- Trial name
- NCT01538849
- Testing
- Esomeprazole 40mg, YH4808 A mg, YH4808 B mg
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Yuhan Corporation
Hospitalized Cases of Angioneurotic Oedema, Pneumonia
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
The purpose of this study is 1. To describe patient characteristics and drug usage among children that are prescribed esomeprazole for the first time and to compare them with patients who are prescribed other proton pump…
- Conditions
- Hospitalized Cases of Angioneurotic Oedema, Pneumonia, Gastroenteritis, Failure to Thrive
- Trial name
- NCT01338363
- Where
- Netherlands
- Volunteers
- 23,470 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origin who have GERD.
- Trial name
- NCT00410592
- Testing
- Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Heartburn
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Trial name
- NCT01249651
- Testing
- esomeprazole 40 mg
- Where
- China
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).
- Trial name
- NCT00625495
- Testing
- Esomeprazole
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
- Trial name
- NCT02860624
- Testing
- 10 mg ilaprazole, 40mg esomeprazole
- Volunteers
- 550 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross Over
This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies.
- Trial name
- NCT00637988
- Testing
- Esomeprazole, Aspirin, Rofecoxib
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.
- Trial name
- NCT07018635
- Testing
- INCB161734, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).
- Trial name
- NCT00644735
- Testing
- Esomeprazole, Lansoprazole
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Reflux, Gastroesophageal
A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression.
- Trial name
- NCT00405119
- Testing
- AH23844 (lavoltidine), NEXIUM (esomeprazole), ZANTAC (ranitidine)
- Where
- 2 sites in Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects
The objectives of this study are: To evaluate the safety and tolerability of single and multiple oral doses of CJ-12420 in healthy male subjects.
- Trial name
- NCT01473173
- Testing
- CJ-12420, Esomeprazole 40mg
- Where
- South Korea
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at…
- Trial name
- NCT00527787
- Testing
- PN400 (VIMOVO), Naproxen
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- POZEN
Erosive Esophagitis, GERD
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.
- Trial name
- NCT02028663
- Testing
- CJ-12420, Esomeprazole
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- HK inno.N Corporation